Holden Comprehensive Cancer Center Accreditations, Distinctions and Designations
National Cancer Institute
Holden Comprehensive Cancer Center is the only NCI-designated comprehensive cancer center in Iowa. This designation recognizes our ability to offer Iowans more cancer treatment options than most U.S. cancer centers, including a vast array of clinical trials of some of the newest therapies.
An emerging body of evidence suggests that treatment at a comprehensive cancer center may offer patients better chances for long-term survival.
American College of Surgeons Commission on Cancer (CoC)
Holden Comprehensive Cancer Center is one of the nation’s longest accredited cancer centers from the Commission on Cancer (CoC), a quality program of the American College of Surgeons.
To achieve CoC accreditation, cancer centers are regularly reviewed to ensure they meet standards that evaluate the services offered by the program.
As a CoC-accredited cancer center, Holden applies a multidisciplinary approach and treats cancer as a complex group of diseases that requires consultation and collaboration among surgeons, medical and radiation oncologists, diagnostic radiologists, pathologists, and other health care professionals that specialize in cancer care.
Patients benefit from having access to clinical trials, screening and prevention events, palliative care, genetic counseling, rehabilitation, oncology nutrition, and survivorship services.
National Accreditation Program for Breast Centers (NAPBC)
University of Iowa Health Care’s Breast Health Center is a NAPBC-accredited center through the American College of Surgeons. The accreditation means we've exceeded a set of standards for leadership, clinical services, research, community outreach, professional education, and quality improvement for our patients.
Each breast center must undergo a rigorous evaluation and review of its performance and meet or exceed nationally recognized quality performance measures for breast cancer treatment.
National Accreditation Program for Rectal Cancers (NAPRC)
Holden Comprehensive Cancer Center is proud to be accredited by the National Accreditation Program for Rectal Cancer through the American College of Surgeons. Highlighting our commitment to excellence in rectal cancer care, this accreditation ensures we meet the highest national standards, providing patients with expert, multidisciplinary treatment.
With access to advanced training, tracking tools, and a network of specialists, we continue to enhance outcomes and lead the way in comprehensive rectal cancer care.
Breast Imaging Center of Excellence
University of Iowa Health Care is a designated a Breast Imaging Center of Excellence by the American College of Radiology. This designation is awarded to breast imaging centers that achieve excellence by seeking and earning accreditation in all the American College of Radiology’s voluntary breast imaging accreditation programs and module, including mammography, stereotactic breast biopsy, breast ultrasound, and breast MRI.
At the Breast Imaging Center of Excellence, we also use the most advanced technologies and techniques, including 3-D mammography (tomosynthesis), for screening and diagnosis.
Foundation for the Accreditation of Cellular Therapy (FACT)
The Foundation for the Accreditation of Cellular Therapy (FACT) is an internally recognized accrediting body for hospitals that perform stem cell transplants.
This accreditation puts the Stem Cell Transplant and Cellular Therapies Program on a select list of institutions that meet the most rigorous standards in every aspect of stem cell therapy, including clinical care, donor management, cell collection, processing, storage, transportation, administration, and cell release.
Pheo Para Alliance Center of Excellence
Pheo Para Alliance has designated University of Iowa Health Care as a Center of Excellence for pediatric and adult cancers—the first designation made in Iowa and the surrounding states.
The program recognizes institutions worldwide for providing cutting-edge, quality, multi-disciplinary care and participating in pheochromocytoma (pheo) or paraganglioma (para) research.